Mysterious illness sidelines Porzingis, Warriors' future in doubt!

Kristaps Porzingis' highly anticipated debut with the Golden State Warriors on February 19 showed glimpses of his immense potential, despite the rust from over a month on the sidelines. Adapting to the team's motion offense and new environment, Porzingis displayed his floor-stretching and rim-protecting capabilities, earning him the "Unicorn" nickname, reminiscent of his time with the New York Knicks and his 2024 championship run with the Boston Celtics. In the nine minutes and forty-eight seconds he played, the Warriors outperformed their opponents by 15 points, a clear indicator of the immediate impact he could have.
However, the underlying issue for Porzingis has consistently been his availability, not his ability. Having missed 110 games over the past two and a half seasons, his current stint with the Warriors has been plagued by a mysterious health condition. The 30-year-old former All-Star was diagnosed last year by Celtics doctors with Postural Orthostatic Tachycardia Syndrome (POTS), an autonomic condition characterized by a dramatic increase in heart rate, dizziness, and persistent fatigue. This condition, believed to have been triggered by an upper respiratory viral illness contracted in late February 2025, manifests as profound exhaustion, which Porzingis himself likened to the fatigue after a full day of hard work.
The symptoms of POTS became apparent even before his full return, with Porzingis yawning uncontrollably during a press conference, apologizing for the perceived rudeness. Following his debut, he woke up sick in his San Francisco hotel room, forcing him to miss the ABC afternoon game against the Denver Nuggets. Despite hopes for a quick return against the Los Angeles Lakers, he was ruled out again due to a general illness, extending his absence to six consecutive games. This ongoing struggle with health has become a significant blow to a Warriors season already hampered by injuries to key players like Jimmy Butler (torn ACL in January) and Stephen Curry (persistent right knee trouble), collectively sidelining $144.4 million in salary and trapping the team in a precarious play-in spot.
The lack of a clear understanding of Porzingis's condition has been challenging for everyone involved. A twist in the narrative emerged when Warriors coach Steve Kerr, after the trade, reportedly called Hawks general manager Onsi Saleh, who denied Porzingis was dealing with POTS. This statement caused internal stir and led Kerr to publicly retract his comments, admitting he was not qualified to discuss medical diagnoses. Porzingis has attempted to manage his condition through proper hydration, nutrition, and sleep. He demonstrated resilience during the 2024 playoffs, returning for 16 minutes in a decisive Game 5 win despite a badly injured ankle that required offseason surgery, and later regaining his rhythm through diligent training and strong performances for Latvia in Eurobasket.
Despite the lingering health questions, the Warriors pursued Porzingis, conducting what they termed "due diligence" on his medical history. General Manager Mike Dunleavy expressed confidence in the team's medical group, stating they were comfortable with the decision to trade for him, viewing him as more than just a rental. The trade involved sending disgruntled Jonathan Kuminga, who was on an expiring contract, to the Atlanta Hawks. The Hawks, who had acquired Porzingis last summer and witnessed his efficient rim-protecting and floor-stretching abilities (averaging 17.1 points in 24.1 minutes with a team-best 5.8 net rating in his 413 minutes), ultimately made him available due to his infrequent presence caused by Achilles tendinitis and the persistent illness.
One month post-trade, the optics have not favored Golden State. As Kuminga excelled with the Hawks, Porzingis remained sidelined, contributing to the Warriors' struggle and pushing them further into "play-in purgatory." This reality, coupled with the prolonged absences of other stars, paints a bleak near-term picture and raises questions about the long-term viability of the aging core. Financially, the Porzingis acquisition, being an expiring deal, also provided the Warriors with flexibility, allowing them to control their books and potentially pursue other trade targets like Giannis Antetokounmpo or Kawhi Leonard in the future. The locker room, however, remains supportive, with Draymond Green emphasizing that there is no pressure on Porzingis to return before he is truly healthy. Porzingis himself is determined to finish the year strong, viewing this as a new chapter in his career.
You may also like...
ESPN Unveils MVP's Groundbreaking Women's Boxing Platform!

Most Valuable Promotions (MVP) is launching MVPW, a new global platform for women's boxing, alongside a multiyear broadc...
Barcelona's Bold Move: Osimhen Eyed as Lewandowski's Successor!

FC Barcelona is actively seeking a new star striker, with Victor Osimhen identified as a key target despite his high val...
Comedy Icons Unite! 'Bridesmaids' Cast Set for Epic Oscars Reunion

The 98th Academy Awards, hosted by Conan O’Brien on March 15, promises a star-studded night including a "Bridesmaids" re...
Daryl Hannah Blasts FX's 'Love Story' Over 'Lies' and 'Misogyny,' Citing Viewer Threats

Daryl Hannah has strongly condemned Ryan Murphy's FX series “Love Story,” accusing it of spreading lies and misogyny thr...
Joselyn Dumas Dazzles in Beaded Kente Gown for Ghana's 69th Independence Day

Ghanaian actress Joselyn Dumas celebrated Ghana's 69th Independence Day in March 2026, stunning in a custom, floor-lengt...
Malawi: Unraveling the Mystery of Shadowy Tycoon Wicknell Chivayo's Power

A controversial Zimbabwean businessman, Wicknell Chivayo, has stirred debate in Malawi with his visible presence alongsi...
Shocking Study: Popular GLP-1 Weight Loss Drugs Linked to Increased Osteoporosis and Gout Risk
:max_bytes(150000):strip_icc()/Health-GettyImages-1688221666-08174a5c481b43a5b01c5a8f2d71f3eb.jpg)
New research indicates that prolonged use of GLP-1 medications like Ozempic and Wegovy may be associated with an increas...
Alarming Discovery: New DNA Variant Drives Most Dementia Cases, Experts Demand Mass Testing

A new study links the APOE gene to accelerated cognitive decline in middle-aged adults, suggesting early testing and int...

